

Supplement Table S1. Clinical characteristics of 1651 non-smokers with lung cancer according to screening status.			
	Screened (n = 81)	Non-Screened (n = 1570)	<i>p</i>-Value
Mean age at diagnosis, years (mean, SD)	59.41 ± 7.41	66.36 ± 12.78	<0.001
Median age at diagnosis, years (range)	66 (42-77)	66 (40-99)	
Gender (n, %)			0.159
Male	24 (29.6%)	589 (37.5%)	
Female	57 (70.4%)	981 (62.5%)	
Alcohol drinking consumption	4 (4.9%)	39 (2.5%)	0.156
Betel nut consumption	0 (0%)	8 (0.5%)	1
Histology			0.002
Adenocarcinoma	79 (97.5%)	1269 (80.8%)	
Squamous cell carcinoma	1 (1.2%)	170 (10.8%)	
Small cell carcinoma	1 (1.2%)	79 (5.0%)	
Other	0	52 (3.3%)	
Adenocarcinoma spectrum			<0.001
AAH	6 (7.4%)	0 (0%)	
AIS	7 (8.6%)	0 (0%)	
MIA	9 (11.1%)	0 (0%)	
IPA	57 (70.4%)	1269 (100%)	
Stage			<0.001
Carcinoma in situ	14 (17.3%)	4 (0.3%)	
I	54 (66.7%)	326 (20.8%)	
II	4 (4.9%)	64 (4.1%)	
III	2 (2.5%)	334 (21.3%)	
IV	7 (8.6%)	842 (53.6%)	
Curative surgery rate	35 (83.3%)	459 (29.2%)	<0.001
Targeted therapy	5 (11.9%)	319 (20.3%)	0.241
Mean tumor size (mm)	16.16 ± 13.74	41.25 ± 23.36	<0.001
Deaths	8 (9.9%)	1159 (73.8%)	<0.001

Mean survival days	892.05 ± 516.24	676.03 ± 600.47	<0.001
Median survival days	825 (30-2599)	517.5 (1-3128)	
Abbreviations: AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; IPA: invasive pulmonary adenocarcinoma; MIA: minimally invasive adenocarcinoma; SD: standard deviation.			

Supplement Table S2. Clinical characteristics of 1232 smokers with lung cancer according to screening status.			
	Screened (n = 12)	Non-Screened (n = 1220)	<i>p</i>-Value
Mean age at diagnosis, years (mean, SD)	63.33 ± 11.83	69.15 ± 13.00	0.118
Median age at diagnosis, years (range)	72 (42-83)	71 (41-99)	
Gender (n, %)			1.000
Male	12 (100%)	1175 (96.3%)	
Female	0 (0%)	45 (3.7%)	
Smoking consumption	12 (100%)	1220 (100%)	
Alcohol drinking consumption	6 (50%)	405 (33.2%)	0.230
Betel nut	3 (25%)	187 (15.3%)	0.411
Histology			0.210
Adenocarcinoma	9 (75%)	744 (61%)	
Squamous cell carcinoma	2 (16.7%)	273 (22.4%)	
Small cell carcinoma	0 (0%)	178 (14.6%)	
Other	1 (8.3%)	25 (2%)	
Adenocarcinoma spectrum			
AAH	0 (0%)	0 (0%)	
AIS	0 (0%)	0 (0%)	
MIA	0 (0%)	0 (0%)	
IPA	9 (75%)	744 (60.9%)	
Stage			<0.001
Carcinoma in situ	0 (0%)	0 (0%)	
I	8 (66.7%)	129 (10.6%)	
II	1 (8.3%)	60 (4.9%)	

III	2 (16.7%)	302 (24.8%)	
IV	1 (8.3%)	729 (59.8%)	
Curative surgery rate	10 (83.3%)	211 (17.3%)	<0.001
Targeted therapy	0 (0%)	197 (16.1%)	0.232
Mean tumor size (mm)	26.75 ± 19.99	51.12 ± 26.60	0.001
Deaths	2 (16.7%)	1047 (85.8%)	<0.001
Mean survival days	646.08 ± 337.21	444.85 ± 468.43	0.064
Median survival days	683 (22-1217)	304 (1-2937)	
Abbreviations: AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; IPA: invasive pulmonary adenocarcinoma; MIA: minimally invasive adenocarcinoma; SD: standard deviation.			